CABR 8-K
Caring Brands, Inc. (CABR)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
(Address of principal executive offices, including zip code)
Registrant’s
telephone number, including area code:
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | ||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | ||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | ||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| The
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 8.01 Other Events.
On August 6, 2026, Caring Brands, Inc., a Nevada corporation, (the “Company”), issued a press release providing an update regarding its issued United States patent portfolio covering the Company’s Hair Enzyme Booster and Photocil product platforms, and related matters. A copy of the press release is filed as Exhibit 99.1 to this Current Report and incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
The following exhibits are being filed herewith:
| Exhibit No. | Description | |
| 99.1 | Press Release, dated August 6, 2026 | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Dated: August 6, 2026 | Caring Brands, Inc. | |
| By: | /s/ Glynn Wilson | |
| Name: | Dr. Glynn Wilson | |
| Title: | Chief Executive Officer | |
Exhibit 99.1
Caring Brands Provides Intellectual Property Portfolio Update
Commercial Patent Portfolio Includes Five Issued U.S. Patents Protecting Core Flagship Platforms Targeting $20B+ Combined Global Dermatology & Hair Care Markets
Fort Pierce, FL (GLOBE NEWSWIRE – August 6, 2026) – Caring Brands Inc. (Nasdaq: CABR) a wellness consumer-products company, today provided an update on its expanding intellectual property (IP) portfolio, which now includes five issued U.S. patents covering two of the Company’s principal product platforms: Hair Enzyme Booster and Photocil.
Four of the issued patents cover Hair Enzyme Booster, while the fifth supports Photocil. Together, these patents establish a strong IP moat supporting Caring Brands’ licensing-led commercialization strategy and ongoing strategic partner discussions. Additional U.S. and international patent applications remain in active prosecution across multiple countries.
Key Product Platforms & Market Opportunities
Hair Enzyme Booster ($1.8B+ Market Opportunity): Covered by a four-patent family protecting compositions and methods relating to sulfotransferase enzyme activity and minoxidil metabolism. Up to 50% to 60% of minoxidil users fail to see optimal results due to low baseline scalp enzyme levels. Designed for use alongside topical minoxidil, Hair Enzyme Booster optimizes the enzymatic environment to boost activity, directly addressing an estimated 80+ million hair loss sufferers in the U.S. alone.
Photocil ($20B+ Dermatology Market Opportunity): Covered by an issued U.S. patent protecting methods and compositions involving selective transmission and filtration of specific ultraviolet (UV) light wavelengths. Photocil functions as a topical narrow-band UV filter engineered for targeted skin health applications, addressing global patient populations of over 125 million psoriasis sufferers and 100 million vitiligo sufferers who rely on safe phototherapy solutions.
Commercial Readiness & Multi-Channel Strategy
Caring Brands is actively advancing operational and partner readiness to support expanded product availability. Building upon established international partnerships, including licensing agreements with global leaders like Taisho Pharmaceutical, ongoing commercialization initiatives include:
| ● | Coordination of scalable third-party manufacturing and supply logistics. | |
| ● | Alignment of packaging, labeling, and regulatory compliance frameworks. | |
| ● | Preparation of comprehensive diligence materials for prospective licensees and regional distributors. | |
| ● | Execution of a hybrid commercial model anchored by primary B2B licensing partnerships and supplemented by targeted direct-to-consumer (DTC) sales via Amazon and select retail channels. |
“Building Caring Brands around proprietary, science-backed solutions addressing immense clinical needs is central to our long-term value creation model,” said Dr. Glynn Wilson, Chief Executive Officer of Caring Brands. “With five issued U.S. patents protecting our flagship platforms across multi-billion-dollar hair care and dermatology markets, our immediate operational focus is translating this strong legal foundation into scalable commercial opportunities, advancing operational readiness, empowering existing partners like Taisho, and securing new licensing agreements globally.”
Caring Brands plans to maintain and expand its intellectual property assets where commercially strategic, aligning future patent filings directly with high-value product development priorities. Note: Patent issuance does not constitute regulatory approval, establish clinical efficacy, or guarantee commercial success. The Company previously disclosed that it is not in compliance with the stockholders’ equity requirement of Nasdaq Listing Rule 5550(b) and that the Nasdaq Staff issued a delisting determination, which the Company has appealed to a Hearings Panel. There can be no assurance that the Company will regain compliance or that its securities will remain listed on Nasdaq. Investors should read the Company’s filings with the SEC, including the risk factors therein, for a fuller description.
About Caring Brands
Caring Brands Inc. is a wellness consumer-products company developing over-the-counter and cosmetic products, including Hair Enzyme Booster, Photocil, CB-101 and NoStingz.
Contact:
Brian
S John
Chief Investment Officer
(561) 896-7616
Forward-Looking Statements
This communication contains forward-looking statements regarding Caring Brands, Inc., including statements concerning the Company’s intellectual property strategy, product development and commercialization, licensing opportunities and potential strategic relationships, the Company’s ability to regain compliance with Nasdaq listing requirements and the outcome of the pending Hearings Panel proceeding, and the activities and commercialization plans of the Company’s existing licensees. Forward-looking statements may be identified by words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “explore,” “evaluate,” “intend,” “may,” “might,” “plan,” “potential,” “project,” “seek,” “should” or “will,” and similar expressions. These statements are based on the Company’s current plans, objectives, estimates and expectations and inherently involve risks and uncertainties, many of which are beyond its control. Actual results and the timing of events could differ materially as a result of these risks and uncertainties, including the outcome of patent prosecution; challenges involving patent validity, enforceability, ownership or scope; regulatory developments; development and manufacturing risks; market acceptance; competition; access to capital; and the other risks described under Item 1A, “Risk Factors,” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed on March 31, 2026, and in its subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, available at www.sec.gov. Investors are cautioned that forward-looking statements are not guarantees of future performance. The statements in this communication speak only as of the date made, and Caring Brands undertakes no obligation to update or supplement them, except as required by law.